华芢生物递表港交所 华泰国际和中信证券担任联席保荐人

Core Viewpoint - Huasheng Biotechnology has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International and CITIC Securities serving as joint sponsors [1] Company Overview - Established in 2012, the company is a biopharmaceutical firm based in China, focusing on the development of protein drugs, particularly in the wound healing sector [1] - The company has two core products in its pipeline: Pro-101-1 for treating burns and Pro-101-2 for diabetic foot ulcers [1] Product Development - Pro-101-1 has completed Phase IIb clinical trials in China and is currently in the clinical trial report confirmation stage [1] - Pro-101-2 is undergoing Phase II clinical trials in China [1] - The company anticipates that its PDGF candidate products will primarily target the Chinese market, with plans to launch Pro-101-1 in the United States [1] Market Position - Pro-101-1 is noted as the fastest-developing PDGF candidate drug for burn treatment in China, where there are currently no commercialized PDGF drugs [1] Intellectual Property - The company has submitted five patent applications for its core products and has obtained two PDGF-related patents and technical data from Jingbang and the Military Academy of Engineering in 2013 [1]